Gain Therapeutics, Inc. (GANX) Debt by Year
Gain Therapeutics, Inc. carried $300K in long-term debt against $20.8M in cash and equivalents at the end of fiscal year 2025. This represents a decrease of 8.6% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Gain Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
GANX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
GANX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $220K-32.4% | $273K-13.1% | $300K-8.6% | $299K-20.6% | $325K-13.3% | $314K-20.8% | $328K-26.9% | $376K-13.5% | $375K-19.6% | $397K-17.0% | $449K-9.3% | $435K-10.1% |
| Cash & Equivalents | $13.1M+95.5% | $16.5M+82.3% | $20.8M+100.6% | $8.8M-26.9% | $6.7M-60.5% | $9.1M-14.8% | $10.4M-11.9% | $12.0M+182.0% | $16.9M+168.0% | $10.6M+77.7% | $11.8M+61.3% | $4.3M-60.7% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Gain Therapeutics, Inc. financials
Frequently Asked Questions
What was Gain Therapeutics, Inc.'s long-term debt in fiscal year 2025?
Gain Therapeutics, Inc. carried $300K in long-term debt against $20.8M in cash and equivalents at the end of fiscal year 2025.
How fast is Gain Therapeutics, Inc.'s long-term debt growing?
Gain Therapeutics, Inc. (GANX) long-term debt fell by 8.6% year over year, from $328K to $300K in fiscal year 2025.
How has Gain Therapeutics, Inc.'s long-term debt changed over the years?
Across the 6 fiscal years this page covers, Gain Therapeutics, Inc. (GANX) long-term debt went from $716K in fiscal year 2020 to $300K in fiscal year 2025.
What was Gain Therapeutics, Inc.'s long-term debt in the most recent quarter?
Gain Therapeutics, Inc. (GANX) reported $220K in long-term debt in Q2 2026. This represents a decrease of 32.4% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Gain Therapeutics, Inc. (GANX) reported on that line in every period on record.